Key Takeaways
- 41% revenue growth, but guidance withheld: Q4 FY25 revenue grew 41.3% YoY driven by new products and volume expansion, yet management declined to confirm the same growth speed for FY26, deferring a broader outlook to the AGM.
- Two new facilities are the FY26 story: The Pune facility (SPL Infusion) is days away from completing validation batches and holds a 90-day order book; the Prague JV (Alevia Healthcare) has begun commercial operations with encouraging early feedback. Both will contribute materially for the first time in FY26.
- Margins and working capital are improving, but specifics are absent: Q4 PAT jumped 74.4% YoY on operating performance and cost optimization, and management expects working capital to improve further on inventory, payables and receivables, though it refused to share exact margin targets.
- The growth engine is product breadth plus geographic reach: 15 new products added in FY25 (total 160), entry into five new geographies, and a Francophone Africa regulatory approval that opens a multi-country opportunity, though revenue from that region is back-end loaded to late FY26.
- What to watch next quarter: The pace of commercial production ramp-up at Pune, the trajectory of Prague JV customer conversions from trial batches, and any quantified FY26 guidance at the AGM.
Revenue Growth & Profitability
- Top-line engine: Q4 FY25 revenue growth of 41.3% YoY and full-year FY25 growth of 28.8% YoY were driven by revenues from newer products and volume expansion of existing products.
- Profit conversion: Q4 PAT growth of 74.4% YoY and FY25 PAT growth of 31.4% reflected broader operating performance, while Q4 EBITDA grew 37.9% due to overall cost optimization.
- Employee cost headwind: Employee costs increased significantly because new hires joined for newer geographies, regulatory team requirements are higher, and intellectual property people joined the marketing field; management expects this to be absorbed by increasing volumes.
- Product mix stability: The injectable/oral mix should remain the same because similar products are being pitched in all markets; injectable has more uptake since volumes begin quickly, but oral is also progressing well.
- Growth speed uncertainty: Management would not confirm the same growth speed for FY26, stating the broader outlook will only be available during the AGM, though it expects the trajectory to be "in the same aspect."
Ashwani Khemka: "The broader outlook will be only available during the AGM time and we are trying our level best to have it maintain, but we cannot confirm the same speed right now. It would be in the same aspect."
New Facilities: Pune & Prague
- Pune facility (SPL Infusion) is at the starting line: The facility is now operational, validation batches are underway and expected to be completed within the next 10 days, and it already has a robust order book covering the next 90 days.
- Pune commercial ramp: Some commercial production is expected in Q1, though volume may be lower because fewer days remain in the quarter; full ramp-up is expected from the second and third quarter onward.
- Prague JV (Alevia Healthcare) is live: The final-stage manufacturing facility was established in FY25, commercial operations have been initiated, and early response is promising with encouraging feedback on trial and commercial batches; multiple prospective customers have visited the facility.
- European cost advantage: Management believes that coming from an Indian manufacturing background, the company can keep running costs low in Europe, enabling it to offer European-label products at a more economical price.
- FY26 contribution: FY26 will be the first year of commercial contribution from the Pune facility, and management expects significant expansion in commercial operations from the Prague JV during the year.
Ashwani Khemka: "Yes. As you are asking everything, and we are also very much eager and by god's grace and hope everything, we should have some commercial production in this first quarter."
Geographic & Regulatory Expansion
- Francophone Africa entry: The facility received site approval from the regulator of a Francophone African nation, enabling market entry into that country and opening doors to multiple other French-speaking African nations.
- Filing pipeline: 48 new products were filed in the Francophone African region during the year.
- Five new geographies: The company entered five new geographies during FY25.
- Near-term geographic focus: Growth from the French African market is expected on the later end of FY26; for the current two to three quarters, the company is majorly focused on existing markets in the Middle East and Latin American zone.
- Strategic learning: Management observed that people are moving into ROW markets more post-COVID as local manufacturing has started in developed markets; having a larger product basket enables expansion of customer lifetime value and entering markets with more strength.
Product Portfolio & Capacity
- Portfolio expansion: 15 new products were added in FY25, bringing the total count to 160; the company plans to add 15 to 20 products in FY26.
- Capacity headroom: The Mumbai plant is operating at 65% utilization and the Dehradun plant at 40%, leaving ample room for volume growth without immediate capex.
- FY27 product launches: Management said it is too soon to comment on planned launches for FY27.
Balance Sheet & Working Capital
- Debt stability: Debt levels for FY26 will remain the same as at March 2025; beyond March 2026, management said it is too early to comment.
- Working capital trajectory: Working capital will be on an improving trend, with further improvement expected on inventory, payables and receivables, though management declined to provide exact inventory details or day-level breakouts on the call.
- Margin disclosure: Management would not share exact margin targets for FY26.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Pune facility commercial production | Validation batches complete within 10 days; some commercial production in Q1, full ramp-up from Q2/Q3 onward | Q1 FY26 for initial production; Q2-Q3 FY26 for full ramp-up |
| Prague JV commercial expansion | Significant expansion in commercial operations | FY26 |
| Product launches | 15 to 20 new products added | FY26 |
| Debt levels | Remain at March 2025 levels | FY26 |
| Working capital | Improving trend on inventory, payables and receivables | FY26 |
| Francophone Africa revenue contribution | Growth expected | Later end of FY26 |
| Broader FY26 outlook | Full guidance provided | At AGM |
Key Metrics
| Metric | Q4 FY25 |
|---|---|
| Revenue | ₹18.2 cr, +41.3% YoY |
| EBITDA | ₹3.1 cr, +37.9% YoY |
| EBITDA margin | 16.8%, vs 17.2% in Q4 FY24 |
| Profit after tax | ₹2.2 cr, +74.4% YoY |
| Revenue (full year FY25) | ₹70.1 cr, +28.8% YoY |
| EBITDA (full year FY25) | ₹11.6 cr, +32.1% YoY |
| EBITDA margin (full year FY25) | 16.5%, vs 16.1% in FY24 |
| Profit after tax (full year FY25) | ₹8.1 cr, +31.4% YoY |
| Export-domestic mix | 72.5% export, 27.5% domestic |
| Injectable-tablet-nutraceutical dosage mix | 71.9% injectable, 27% tablet, 1% nutraceutical |
| New products added in FY25 | 15, total portfolio now at 160 products |
| New geographies entered in FY25 | 5 |
| Capacity utilization, Mumbai plant | 65% |
| Capacity utilization, Dehradun plant | 40%, expected to ramp up to 50–55% |
| Products filed in Francophone Africa | 48 during FY25 |
| Capex for Pune HAL JV | ₹30–35 cr incurred in FY25 |